Elder Pharmaceuticals, has received the Certificate of Suitability (COS) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for Diosmin API. The global market size of this finished product is around $500 million of which, the European markets accounts for approximately $225 million. Diosmin is predominantly a prescription medication in some European countries and is also sold as a nutritional supplement in rest of Europe.
Currently, the company has customers throughout the world, viz. Southeast Asia, Africa and Latin American region. “COS” approval for Diosmin API will enable the doors of European region to open offer for Elder, thus enabling the company to expand its global market share.
Diosmin, a semi-synthetic drug, is a member of the flavonoid family. It can be isolated from various plant sources or derived from the flavanoid hesperidins. It is an oral phlebotropic drug used in the treatment of venous disease, I.e. Chronic Venous Insufficiency and Hemorrhoidal Disease (HD).
